Q-omics provides the consensus-scored DPP3 profile across patient tissues and cancer cell-line models. DPP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, DPP3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DPP3 RNA expression shows 18,116 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, HNSC, and ACC as cancer lineages where DPP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPP3 survival associations across molecular data types. DPP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPP3 RNA expression–survival associations across cancer types. High DPP3 expression shows unfavorable associations in LUAD, UVM, KICH, LGG and LAML, but favorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify STAD as the clearest survival context for DPP3 RNA expression.
This table summarizes DPP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DPP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPP3 shows higher tumor expression in HNSC, BLCA, LIHC, KIRP, LUSC and STAD. The HNSC box plot shows higher DPP3 RNA expression in tumor versus normal tissue (log2 FC = +1.195, t-test p < 0.001).
This table shows molecular features associated with DPP3 in patient tissues and cancer cell lines. In patient samples, DPP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
